| Stage | COR | % of rev | MCK | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $84.8B | 100.00% | $105B | 100.00% | MCK ×1.24 |
| Gross profit | $3.6B | 4.26% | $3.7B | 3.50% | COR +0.8pp |
| Operating income | $1.1B | 1.32% | $1.3B | 1.25% | COR +0.1pp |
| Pre-tax income | $996M | 1.18% | $1.3B | 1.24% | MCK +0.1pp |
| Net income | $777M | 0.92% | $1.0B | 0.98% | MCK +0.1pp |
| Stage | COR | MCK | Gap · A − B |
|---|---|---|---|
| Revenue | $84.8B100.00% | $105B100.00% | MCK ×1.24 |
| Gross profit | 4.26%$3.6B | 3.50%$3.7B | COR +0.8pp |
| Operating income | 1.32%$1.1B | 1.25%$1.3B | COR +0.1pp |
| Pre-tax income | 1.18%$996M | 1.24%$1.3B | MCK +0.1pp |
| Net income |
| 0.92%$777M |
| 0.98%$1.0B |
| MCK +0.1pp |
COR · CTXR 10-KDec 23 '25
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”
MCK · CTXR 10-KDec 23 '25
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”